Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Voroneanu, Luminita ^a   Nistor, Ionut ^a   Dumea, Raluca ^a   Apetrii, Mugurel ^a   Covic, Adrian ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIPID; SILYMARIN; ANTIOXIDANT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; META ANALYSIS (TOPIC); MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SILYBUM MARIANUM; SYSTEMATIC REVIEW; DIABETES MELLITUS, TYPE 2; META ANALYSIS; METABOLISM; TREATMENT OUTCOME;

ANTIOXIDANTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SILYMARIN; TREATMENT OUTCOME;

EID: 84975322192     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/5147468     Document Type: Review

References (42)

1. http://www. idf. org.
2. http://www. cdc. gov/diabetes/pubs/statsreport14/national-diabetes-report-web. pdf.
3. http://www. euro. who. int.
4. American Diabetes Association, "Economic costs of diabetes in the U. S. in 2012, " Diabetes Care, vol. 36, no. 4, pp. 1033-1046, 2013.
5. K. Flora, M. Hahn, H. Rosen, K. Benner, and K. Benner, "Milk thistle (Silybummarianum) for the therapy of liver disease, "The American Journal of Gastroenterology, vol. 93, pp. 139-143, 1998.
6. N.-C. Kim, T. N. Graf, C. M. Sparacino, M. C. Wani, and M. E. Wall, "Complete isolation and characterization of silybins and isosilybins frommilk thistle (Silybum marianum), " Organic and Biomolecular Chemistry, vol. 1, no. 10, pp. 1684-1689, 2003.
7. K. Wellington and B. J. Adis, "Silymarin: a review of its clinical properties in the management of hepatic disorders, " BioDrugs, vol. 15, no. 7, pp. 465-489, 2001.
8. E. Bosisio, C. Benelli, and O. Pirola, "Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes, " Pharmacological Research, vol. 25, no. 2, pp. 147-165, 1992.
9. S. A. Tasduq, K. Peerzada, S. Koul, R. Bhat, and R. K. Johri, "Biochemicalmanifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin, " Hepatology Research, vol. 31, no. 3, pp. 132-135, 2005.
10. P. V. Kiruthiga, R. B. Shafreen, S. K. Pandian, and K. P. Devi, "Silymarin protection against major reactive oxygen species released by environmental toxins: exogenous H2O2 exposure in erythrocytes, " Basic & Clinical Pharmacology & Toxicology, vol. 100, no. 6, pp. 414-419, 2007.
11. P. V. Kiruthiga, S. K. Pandian, and K. P. Devi, "Silymarin protects PBMC against B(a)P induced toxicity by replenishing redox status and modulating glutathione metabolizing enzymes-an in vitro study, " Toxicology and Applied Pharmacology, vol. 247, no. 2, pp. 116-128, 2010.
12. A. O. Abdel-Zaher, R. H. Abdel-Hady, M. M. Mahmoud, and M. M. Y. Farrag, "The potential protective role of alpha-lipoic acid against acetaminophen-induced hepatic and renal damage, " Toxicology, vol. 243, no. 3, pp. 261-270, 2008.
13. S. Al-Jassabi, A. Saad, M. S. Azirun, and A. Al-Omari, "The role of Silymarin in prevention ofAlloxan-induced diabetes mellitus in Balb/C mice, " American-Eurasian Journal of Toxicological Sciences, vol. 3, no. 3, pp. 172-176, 2011.
14. K. Khazim, Y. Gorin, R. C. Cavaglieri, H. E. Abboud, and P. Fanti, "The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo, " American Journal of Physiology-Renal Physiology, vol. 305, no. 5, pp. F691-F700, 2013.
15. F. Turgut, O. Bayrak, F. Catal et al., "Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats, " International Urology and Nephrology, vol. 40, no. 2, pp. 453-460, 2008.
16. T. Nishikawa, D. Edelstein, X. L. Du et al., "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage, " Nature, vol. 404, no. 6779, pp. 787-790, 2000.
17. F. Malihi, A. Hosseini-Tabatabaei, H. Esmaily, R. Khorasani, M. Baeeri, and M. Abdollahi, "Improvement of inflammatory and toxic stress biomarkers by silymarin in a murine model of type one diabetes mellitus, " Central European Journal of Biology, vol. 4, no. 3, pp. 369-380, 2009.
18. J. F. Navarro-González, C. Mora-Fernández, M. M. De Fuentes, and J. García-Pérez, "Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy, " Nature Reviews Nephrology, vol. 7, no. 6, pp. 327-340, 2011.
19. M. K. Fallahzadeh, B. Dormanesh, M. M. Sagheb et al., "Effect of addition of silymarin to renin-angiotensin systeminhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial, " American Journal of Kidney Diseases, vol. 60, no. 6, pp. 896-903, 2012.
20. J.-D. Jia, M. Bauer, J. J. Cho et al., "Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen 1(I) and TIMP-1, " Journal of Hepatology, vol. 35, no. 3, pp. 392-398, 2001.
21. J. P. Liu, M. Zhang, W. Y. Wang, and S. Grimsgaard, "Chinese herbal medicines for type 2 diabetes mellitus, " Cochrane Database of Systematic Reviews, no. 3, Article ID CD003642, 2004.
22. D.-H. Jeong, G.-P. Lee, W.-I. Jeong et al., "Alterations of mast cells and TGF-1 on the silymarin treatment for CCl4-induced hepatic fibrosis, " World Journal of Gastroenterology, vol. 11, no. 8, pp. 1141-1148, 2005.
23. S. Clichici, D. Olteanu, A.-L. Nagy, A. Oros, A. Filip, and P. A. Mircea, "Silymarin inhibits the progression of fibrosis in the early stages of liver injury in CCl4-treated rats, " Journal of Medicinal Food, vol. 18, no. 3, pp. 290-298, 2015.
24. R. E. Gilbert, A. Akdeniz, T. J. Allen, and G. Jerums, "Urinary transforming growth factor- in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology, " Nephrology Dialysis Transplantation, vol. 16, no. 12, pp. 2442-2443, 2001.
25. B. P. Jacobs, C. Dennehy, G. Ramirez, J. Sapp, and V. A. Lawrence, "Milk thistle for the treatment of liver disease: a systematic review and meta-analysis, " The American Journal of Medicine, vol. 113, no. 6, pp. 506-515, 2002.
26. M. Velussi, A. M. Cernigoi, D. M. Ariella, F. Dapas, C. Caffau, and M. Zilli, "Long-term (12 months) treatment with an antioxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need andmalondialdehyde levels in cirrhotic diabetic patients, " Journal of Hepatology, vol. 26, no. 4, pp. 871-879, 1997.
27. N. Suksomboon, N. Poolsup, S. Boonkaew, and C. C. Suthisisang, "Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes, " Journal of Ethnopharmacology, vol. 137, no. 3, pp. 1328-1333, 2011.
28. H. F. Huseini, B. Larijani, R. Heshmat et al., "The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebocontrolled, clinical trial, " Phytotherapy Research, vol. 20, no. 12, pp. 1036-1039, 2006.
29. S. A.-R. Hussain, "Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes, " Journal of Medicinal Food, vol. 10, no. 3, pp. 543-547, 2007.
30. S. Ebrahimpour Koujan, B. P. Gargari, M. Mobasseri, H. Valizadeh, and M. Asghari-Jafarabadi, "Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial, " Phytomedicine, vol. 22, no. 2, pp. 290-296, 2015.
31. E. Mannucci, I. Dicembrini, A. Lauria, and P. Pozzilli, "Is glucose control important for prevention of cardiovascular disease in diabetes" Diabetes Care, vol. 36, supplement 2, pp. S259-S263, 2013.
32. H. C. Gerstein, M. E. Miller, R. P. Byington et al., "Effects of intensive glucose lowering in type 2 diabetes, " The New England Journal of Medicine, vol. 358, no. 24, pp. 2545-2559, 2008.
33. V. Papademetriou, L. Lovato, M. Doumas et al., "Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes, " Kidney International, vol. 87, no. 3, pp. 649-659, 2015.
34. B. Hemmingsen, S. S. Lund, C. Gluud et al., "Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials, " British Medical Journal, vol. 343, Article ID d6898, 2011.
35. C. Baigent, A. Keech, P. M. Kearney et al., "Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from90, 056 participants in 14 randomised trials of statins, " The Lancet, vol. 366, no. 9493, pp. 1267-1268, 2005.
36. B. Mihaylova, J. Emberson, L. Blackwell et al., "The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, " The Lancet, vol. 380, no. 9841, pp. 581-590, 2012.
37. P. M. Kearney, L. Blackwell, R. Collins et al., "Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: ameta-analysis, " The Lancet, vol. 371, no. 9607, pp. 112-117, 2008.
38. M. Strazzabosco, "Effects of silybinin on biliary lipid composition, " Journal of Hepatology, vol. 12, pp. 290-292, 1999.
39. C. Vaughu, A. M. Jr. Gotto, and C. T. Basson, "The evolving role of silymarin in management of atherosclerosis, " Journal of the American College of Cardiology, vol. 36, no. 1, pp. 1-5, 2006.
40. F. Lirussi, A. Beccarello, G. Zanette et al., "Silybin-betacyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent, " Diabetes, Nutrition&Metabolism, vol. 15, no. 4, pp. 222-231, 2002.
41. H. M. Alkuraishy and S. Alwindy, "Beneficial effects of silymarin on lipid profile in hyperlipidemic patients: placebo controlled clinical trail, " Webmed Central Pharmacology, vol. 3, no. 2, Article IDWMC002966, 2012.
42. H. J. Suh, S. Y. Cho, E. Y. Kim, and H. S. Choi, "Blockade of lipid accumulation by silibinin in adipocytes and zebrafish, " Chemico-Biological Interactions, vol. 227, pp. 53-62, 2015.